Table 2:

Studies demonstrating drug specific variation in latency^*.

	Hepatocellular	Cholestatic/ mixed	P-value**	Reference
Statins	n=14 153 (0 to 1866)	n=8 153 (0 to 3600)	p=0.913	Russo et al.[38]
Azithromycin	n=10 20 (38 to 65)	n=8 17 (2 to 38)	p=0.887	Martinez et al. [39]
Cefazolin	n=3 23 (21 to 23)	n=16 20 (6 to 29)	p=0.487	Alqahtani SA, et al.[40]
Quinolones	n=4 13 (5 to 27)	n=8 2 (1 to 11)	p=0.215	Orman ES, et al.[41]
Cyproterone acetate (CPA)	n=20 150 (105 to 215)	n=2 150 & 151	p=0.866	Bessone F, et al. [42]
Ceftriaxone	n=2 11 & 21	n=13 8 (4 to 14)	p=0.229.	Nakaharai K, et al. [43]

^*Latency is measured in days from drug start to abnormal liver tests

^**p-value for hepatocellular injury versus cholestatic injury (defined as R value: ALT times upper limit of normal (ULN) / alkaline phosphatase times upper limit of normal (ULN).